GSK hails promising trial results for hepatitis B treatment
Drug could provide a cure for condition that affects more than 250mn people
Related reading
How GSK is rebuilding its cancer business
A decade after exiting oncology, the UK pharma group is betting that R&D and acquisitions will help it hit sales of £40bn
GSK blood cancer drug reapproved by EU regulator
Blenrep had been removed from sale after a trial failed to show it was superior to other treatments
BioNTech settles Covid-19 patent dispute with CureVac
UK’s GSK will receive $370mn and 1% of sales of some vaccines as part of the deal
US health agency reapproves GSK blood cancer drug after new trial
FDA gives go-ahead to UK drugmaker’s multiple myeloma treatment Blenrep
Gilead nears up to $2bn deal for autoimmune biotech Ouro Medicines
California-based drugmaker takes advantage of surging share price to strike takeovers after a quiet couple of years
Bayer soars on promising trial results for stroke prevention drug
Findings are respite for German conglomerate facing sliding sales of blockbuster drugs and US legal challenges